Docket No. 55022-DIV (71526)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

S. Mori et al.

SERIAL NO.

10/625,821

GROUP:

1638

FILED:

July 22, 2003

**EXAMINER:** Not Yet Assigned

FOR:

METHOD FOR TRANSFORMING PLANT, THE RESULTANT

PLANT AND GENE THEREOF

Mail Stop: Missing Parts **Commissioner for Patents** P.O. Box 1450

Alexandria, Virginia 22313-1450

# SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1	(X)	This replies	to the Office	e Letter DATED	March 26, 2004	
ι.	$I \Delta I I$		to the Onlice		<u> </u>	

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

[X] A copy of the Office Letter is enclosed.

### IDENTIFICATION OF PERSON MAKING STATEMENT

2.	I, Christine C. O'Da	<u>'</u>		
		(type or print name of person signing below)		
	state the following:			

# ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

(check each item as applicable)

(Submission-Nucleotide and/or Amino Acid Sequence--page 1 of 5)

A.	[ ] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.			
B.	B. [] An amendment to the description and/or claims, wherein reference is made to the sequence use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).			e sequence by
C.	C. [ ] A copy of each "Sequence Listing" submitted for this application in computer readable for accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.			dable form, in
D. [X] Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the correadable copy(ies) from applicant's other application identified as follows:			the computer	
	In re application of Application No.: Filed: For:	09/646,825 September 22, 2000	FORMING PLANT, THE AND GENE THEREOF	
The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:				
Comp	outer Readable Form		"Sequenc	e Identifier"
_	outer Readable Form		<u>-</u>	e Identifier" application)
(other		NOS. 1-38	<u>-</u>	application)
(other	application)  N 09/646,825 / SEQ ID N  "If the computer readable application of the applicate readable form in lieu of filt be accompanied by a letter	form of a new application is to int on file in the Office, refere ling a duplicate computer reada	(this	application) S. 1-38 form of another n and computer application shall
(other USSN NOTE:	application)  1 09/646,825 / SEQ ID 1  "If the computer readable application of the application areadable form in lieu of fill be accompanied by a letter shall be completely identification."  [ ] A statement that	form of a new application is to int on file in the Office, refere ling a duplicate computer reada making such reference to the ot ed." 37 C.F.R. Section 1.821(e).	(this USSN 10/625,821 / SEQ ID NO. to be identical with the computer readable nee maybe made to the other application ble form in the new application. The new other application and computer readable for application and computer readable for quence Listing" submitted and each	application) S. 1-38 form of another n and computer application shall m, both of which
(other USSN NOTE:	"If the computer readable application of the applic	form of a new application is to ant on file in the Office, refere ing a duplicate computer readar making such reference to the otted." 37 C.F.R. Section 1.821(e).  the content of each "Set the same, as required in 37 tatement is not made by a is verified as required in 3	(this USSN 10/625,821 / SEQ ID NOS to be identical with the computer readable nee maybe made to the other application ble form in the new application. The new other application and computer readable for quence Listing" submitted and early C.F.R. Section 1.821(g).  person registered to practice before 7 C.F.R. Section 1.821(b). ling the requirement under 37 C.	application) S. 1-38 form of another n and computer application shall m, both of which ach computer

# STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

## 4. I hereby state:

(complete applicable item A and/or B)

- A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

#### **STATUS**

5.	Applicant is		
	[ ] a small entity. [X] other than a small entity.		

#### **EXTENSION OF TERM**

6.

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec.10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. Section 1.645 for extensions of time in interference proceedings and 37 C.F.R. Section 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(complete (a) or (b) as applicable)

	(a)				er 37 C.F.R. Section nonths checked below	1.136 (fees: 37 C.F.R. v:
		Extensior (months)			ee for nall entity	
	] ] ] ]	] three mor	hs \$ 400 oths \$ 920	.00 \$ .00 \$	55.00 200.00 460.00 720.00	· ,
				Fee \$	_	
If a	n ad	ditional extens	ion of time is requ	iired, please conside	this a petition theref	for.
			(check and	d complete the next i	tem, if applicable)	
			is deducted	from the total fee		and the fee paid therefor of months of extension now uest \$
				OR		
	(b)	being ma		the possibility that a		this conditional petition is tently overlooked the need
				FEE PAYME	NT	
8.	[]	Attached is a	check in the sum	of\$		
	[ ] Charge Account No the sum of \$ A duplicate of this transmittal is attached.					
				FEE DEFICIEN	NCY	
9. <i>NO</i> 2	TE:	additional time of deficiency is note included, process charges prior to	consumed in making used and corrected, the sing delays are encou	p the original deficiency application is held aban intered in returning the p uthorization to charge th	. If the maximum, six-mor doned. In those instances papers to the PTO finance	al fees are necessary to cover the nth period has expired before the where authorization to charge is e Branch in order to apply these fee deficiency should be checked.
10.	[X]	If any addition	nal extension and/	or fee is required, ch	arge Account No	04-1105 .
				(Submissio	n-Nucleotide and/or Ami	no Acid Sequence—page 4 of 5)

# SIGNATURE(s)

	Christine C. O'Day
	(type or print name of person signing statement)
	Chrix C.h
5-25-04	Signature
Date EDWARDS & ANGELL, LLP P.O. Box 55874 P.O. Address of Signatory	
Boston, MA_02205	
(If applicable) Tel. No.: (617) 439-4444	<ul> <li>[ ] Inventor</li> <li>[ ] Assignee of complete interest</li> <li>[ ] Person authorized to sign on behalf of assignee</li> <li>[ ] Practitioner of record</li> </ul>
Reg. No. 38,256 Customer No.: 21874	[ ] Filed under Rule 34(a) [X] Registration No. 38,256 [ ] Other
(complete	e the following, if applicable)
(type name of assignee)	_
Address of assignee .	_ _
Title of person authorized to sign on behalf of assignee	
A "STATEMENT UNDER 37 C.F.R. Section Assignment recorded in PTO on	· ·
Reel Frame _	



### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Viguda 22313-1450 www.uspik.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/625,821

07/22/2003

Satoshi Mori

55022-DIV (71526)

21874 EDWARDS & ANGELL, LLP P.O. BOX 55874 BOSTON, MA 02205



CONFIRMATION NO. 7795
FORMALITIES LETTER
\*OC000000012202273\*

Date Mailed: 03/26/2004

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

# Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Customer Service Cent

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE